Physician profile
David Schwimmer
NPI 1245641380
$24,281.61
in general payments reported to CMS, 2019-2025
35 companies · $15K in 2025
The $15K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $590 · 2021: $1,785 · 2022: $2,277 · 2023: $2,441 · 2024: $1,631 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $5,187 · Travel and Lodging: $433 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,775.00 |
| Food and Beverage | $5,186.89 |
| Travel and Lodging | $433.35 |
| Education | $108.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17,793.11 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,561.80 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $833.51 | 2021-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $624.04 | 2020-2024 | Xifaxan, Trulance |
| Celgene Corporation | $416.98 | 2021-2023 | Zeposia |
| Qol Medical, LLC | $406.75 | 2020-2024 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $287.93 | 2020-2024 | Ocaliva |
| Pfizer INC. | $249.81 | 2021-2024 | |
| Genzyme Corporation | $220.01 | 2022-2024 | |
| Nestle Healthcare Nutrition INC. | $170.94 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $170.03 | 2021-2024 | Linzess |
| Janssen Scientific Affairs, LLC | $158.11 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $140.46 | 2022-2023 | |
| Braintree Laboratories, INC. | $139.94 | 2020-2021 | |
| Redhill Biopharma INC. | $137.96 | 2020-2023 | Talicia, Aemcolo, Movantik |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $125.41 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $84.33 | 2022-2023 | Dupixent |
| Evoke Pharma, INC. | $71.46 | 2020-2021 | |
| Daiichi Sankyo INC. | $71.03 | 2021-2023 | Injectafer |
| Lilly USA, LLC | $60.47 | 2024-2025 | Omvoh, Zepbound |
| Merck Sharp & Dohme LLC | $59.52 | 2022-2024 | Dificid, Zinplava |
| Boston Scientific Corporation | $59.00 | 2019 | |
| Palette Life Sciences, INC. | $58.57 | 2022 | |
| Phathom Pharmaceuticals, INC. | $49.01 | 2024 | Voquezna |
| Fresenius Kabi USA, LLC | $45.12 | 2023 | Idacio |
| Ardelyx, INC. | $43.82 | 2023-2024 | Ibsrela |
| Ucb, INC. | $39.77 | 2021 | |
| Vivus LLC | $35.00 | 2021-2022 | |
| Gilead Sciences, INC. | $32.26 | 2020 | |
| Madrigal Pharmaceuticals | $31.36 | 2025 | Rezdiffra |
| Amgen INC. | $26.45 | 2023 | Avsola |
| Pharmacosmos Therapeutics INC. | $24.50 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.28 | 2023 | Andexxa |
| Ferring Pharmaceuticals INC. | $17.96 | 2022 | |
| Novo Nordisk INC | $14.91 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schwimmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.